24 REAL-WORLD COMPARISON OF TOFACITINIB VERSUS USTEKINUMAB AMONG ULCERATIVE COLITIS PATIENTS WITH PRIOR ANTI-TUMOR NECROSIS FACTOR ALPHA AND ANTI-INTEGRIN TREATMENT FAILURE: A PROPENSITY SCORE-ADJUSTED ANALYSIS

Autor:	Rahul S. Dalal, Hannah Goodrick, Jennifer Mitri, Jessica R. Allegretti
Rok vydání:	2021
Předmět:	Anti tumor necrosis factor alpha medicine.medical_specialty Tofacitinib Hepatology business.industry Gastroenterology Anti integrin medicine.disease Ulcerative colitis Treatment failure Internal medicine Ustekinumab Propensity score matching Medicine business medicine.drug
Zdroj:	Gastroenterology. 160:S-5
ISSN:	0016-5085
DOI:	10.1016/s0016-5085(21)00761-7
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2f8000d80a1ee1f1cb8abd7b13a1e6bb https://doi.org/10.1016/s0016-5085(21)00761-7 Zobrazit plný text záznamu